Since definitive pathology was only available for positive participants (f-Hb ≥20 μg/g), we used truncated regression methods to estimate the influence of bowel pathology on f-Hb and the sensitivity of different thresholds to CRC and HRA. The gene discussed is GSTM1; the disease is colorectal carcinoma.